Introduction
============

Targeting angiogenesis, the underlying mechanism promoting choroidal neovascularisation is a new treatment alternative in neovascular age-related macular degeneration (AMD). Of the available antivascular endothelial growth factor (anti-VEGF) drugs ([@b14-opth-1-167]; [@b2-opth-1-167]; [@b46-opth-1-167]), ranibizumab has been demonstrated to stabilize/or improve visual acuity and anatomical outcomes in patients with neovascular (AMD), in large clinical trials ([@b4-opth-1-167]; [@b34-opth-1-167], [@b35-opth-1-167]). Ranibizumab is a murine, monoclonal anti-VEGF antibody given intravitreally every four weeks. Its monthly application is based upon studies in primates that showed its rapid distribution in the retina (6--24 hours) and three day half life before its clearance from all ocular compartments ([@b11-opth-1-167]). While its most favourable outcomes (prevention of visual acuity loss in 95% of patients and improvement in visual acuity in 25%--30% of patients) have been described when given monthly over a period of two years ([@b4-opth-1-167]; [@b34-opth-1-167]), new treatment strategies in combination with photodynamic therapy are being extensively investigated ([@b6-opth-1-167]; [@b19-opth-1-167]). Mild adverse effects after treatment with ranibizumab, such as conjunctival hyperaemia and subconjunctival haemorrhage have been reported in about 80% of patients and serious complications such as endophthalmitis and uveitis were evident in about 1%--1.3% ([@b36-opth-1-167]). Ongoing clinical trials are currently investigating the effect of less frequent dosing regimens. These studies indicate that optical coherence tomography (OCT) is helpful in retreatment decisions ([@b22-opth-1-167]; [@b35-opth-1-167]).

While studies with anti-VEGF drugs have investigated its toxicity and penetration in animals ([@b24-opth-1-167]; [@b43-opth-1-167]), only two studies have measured local cellular function in humans. Both studies suggest further evaluation of neuroretinal function ([@b26-opth-1-167]; [@b30-opth-1-167]). [@b26-opth-1-167] showed that there was no deterioration of neuroretinal function after one intravitreal treatment with bevacizumab, another anti-VEGF drug which has been used 'off-label' for treatment of AMD ([@b34-opth-1-167]). They showed some small improvement of central neuroretinal activity compared with baseline which they attributed to variability in the results rather than a recovery of function. The authors concluded that testing over a longer term was necessary ([@b26-opth-1-167]). [@b30-opth-1-167] found no improvement in retinal function as measured using the mfERG after one bevacizumab injection after three months in 56% of their patients. While there was some improvement in amplitude on average compared with baseline, they attributed this to a decrease in macular edema rather than recovery of neuroretinal function. No published study has evaluated neuroretinal function after multiple treatments with ranibizumab.

In the small series of neovascular AMD patients considered here, we extend the information about neuroretinal function after anti-VEGF therapy by monitoring patients who received several treatments with ranibizumab. The follow up of three treatments in this study is based on large clinical trials that currently test the drug efficacy after an induction period of three monthly injections followed by quarterly injections ([@b37-opth-1-167]). Besides well established visual acuity measures and OCT for monitoring treatment effects, we investigated contrast sensitivity and objectively documented central and peripheral neuroretinal function (up to 25 degree in diameter) with the multifocal electroretinogram (mfERG). A functional documentation of central and peripheral retinal areas is necessary to estimate a patient's reading and mobility performance. So far, large clinical trials investigating anti-VEGF therapy have only reported visual acuity as a functional outcome measure. Visual acuity, however, reflects function of only about the central 1 degree of the retina.

In addition to neuroretinal activity, the mfERG reflects hypoxic effects on retinal function ([@b8-opth-1-167]), which are likely to occur when there is choroidal atrophy. The latter has been described in relation to deprivation of VEGF from the choroid as it may occur during anti-VEGF therapy ([@b28-opth-1-167]; [@b25-opth-1-167]).

Methods
=======

Participants
------------

We investigated three patients (1 female, 2 male) aged 80 y (AMD 1), 77 y (AMD 2) and 74 y (AMD 3), respectively. All patients had a diagnosis of neovascular AMD as assessed ophthalmoscopically and by fluorescein angiography. Patients were treated with 0.3 mg ranibizumab intravitreally by an ophthalmologist (AG) according to the recommended protocol ([@b34-opth-1-167]). Participants were in good general health although one patient (AMD 3) had primary chronic open angle glaucoma which was well controlled by topical medication. Two of the participants (AMD 2 and AMD 3) had a new choroidal neovascular membrane (CNV) and were treated with first line therapy ranibizumab whereas patient 1 (AMD 1) had a recurrent CNV following three preceding photodynamic therapies before she received ranibizumab. Twenty participants (aged between 58 and 77 years, mean 69 ± 5) contributed to the healthy control group.

All patients gave written informed consent and the study was conducted in accordance with the tenets of the Declaration of Helsinki and the requirements of the Queensland University of Technology Human Research Ethics Committee.

Tests
-----

All tests were performed under the instructions of the same researcher (BF). Visual acuity (VA) was assessed with Bailey Lovie charts ([@b3-opth-1-167]) at a starting distance of 6 m and contrast sensitivity with Pelli Robson charts at 3 m ([@b32-opth-1-167]). An improvement in visual acuity was defined as an increase of three lines (15 letters) ([@b37-opth-1-167]) and improvement in contrast sensitivity as an increase of 6 letters ([@b39-opth-1-167]). Macular thickness was measured using optical coherence tomography (OCT, Stratus III, Zeiss, Germany) ([@b18-opth-1-167]).

To evaluate neuroretinal activity we used the mfERG (VERIS, EDI, Redwood City, USA). The mfERG gives a topographical map of local neuroretinal function of the posterior pole. The waveform of the conventional fast flicker application is thought to reflect photoreceptor function and primarily ON and OFF bipolar cell function ([@b20-opth-1-167]). In contrast to the full-field ERG which gives a global retinal response, the mfERG allows the derivation of many local areas of the central and peripheral retina between 25 to 50 degrees in diameter. The mfERG has been shown to be particularly useful in documenting treatment effects in the central and peripheral retina in AMD and diabetes ([@b15-opth-1-167]; [@b29-opth-1-167]; [@b7-opth-1-167]; [@b26-opth-1-167]).

The visual stimulus of the mfERG consisted of 103-scaled black and white hexagons displayed on a calibrated 7-inch CRT monitor. [Figure 1](#f1-opth-1-167){ref-type="fig"} demonstrates the stimulus array extending to 25 degrees in diameter (left), the local 103 waveform responses corresponding with each of the stimulated retinal areas (middle), and a three dimensional response density map of the retinal responses. The responses are higher centrally and decrease with increasing eccentricity according to the topographical distribution of cone photoreceptors and their associated postreceptoral pathways ([@b45-opth-1-167]).

Participants were instructed to fixate on a large central cross at the center of a CRT monitor and were corrected for the test distance using an eye monitor/refraction unit. Pupils were dilated using tropicamide 0.5% and phenylephrine 2.5%. The black and white hexagons flickered according to a pseudorandom m-sequence where the CRT monitor screen was refreshed every 13.33 ms (75 Hz frame rate) ([@b48-opth-1-167]). The mfERG was recorded monocularly with DTL (Dawson-Trick-Litzkow) thread electrodes that were placed across the bulbar conjunctiva. The reference Ag-AgCl cup electrodes were placed on the temple close to the testing eye and the ground was placed on the forehead. Retinal signals were band pass filtered (10--300 Hz), sampled every 0.83 ms and amplified (50,000x, Grass amplifier). Recordings were made under ambient room light conditions. An eye camera and the on-line signal were used for monitoring fixation and blinks; small eye movements and artefacts detected during the recording caused signal segments to be rejected and re-recorded.

We analysed N1P1 peak to trough response densities (amplitudes per unit retinal area, in nV/deg^2^) and peak P1 implicit times (time from the onset of the stimulus to the first positive peak, in ms) as shown in [Figure 2](#f2-opth-1-167){ref-type="fig"} (left). Before analysing the first order kernel (mean local responses to all stimuli in a stimulus cycle) amplitudes and implicit times, one spatial averaging procedure (ratio = 6) and one noise reduction procedure were performed on the raw mfERG data (see [@b45-opth-1-167]).

Statistical analysis
--------------------

Main outcome variables were means of N1P1 amplitudes and peak P1 implicit times. For better signal to noise ratio, N1P1 amplitude and P1 implicit time waveform responses were averaged into a central (∼13.5°) and peripheral area (∼13.5°−25°) in diameter ([Figure 2](#f2-opth-1-167){ref-type="fig"}, right).

For statistical analysis, central and peripheral N1P1 amplitude response densities and P1 implicit time averages of each AMD patient were compared with responses of the healthy age-similar group before and after three treatments. The central and peripheral N1P1 amplitudes and P1 implicit times were also compared within each AMD patient's pre-and second and third treatment. A repeated measures ANOVA (SPSS-14) was used to identify a significant (main) effect between the treatments and retinal locations (central and peripheral) between each AMD patient and the healthy control group before and after three treatments and within each AMD patient's treatments.

Results
=======

Visual acuity, contrast sensitivity, optical coherence tomography (OCT), and the mfERG were performed before (a week or less) and three to four weeks after each of the three treatments. One patient (AMD 3) was not able to perform a mfERG after the first treatment because of illness unrelated to the treatment. For uniform presentation of mfERG data, the results are reported before treatment, and after the second and third treatment in all participants.

Visual acuity improved by 6 lines and contrast sensitivity by 10 letters in one patient (AMD 3) and remained stable in AMD 1 and AMD 2 after three treatments with ranibizumab ([Table 1](#t1-opth-1-167){ref-type="table"}). Decreased central macular thickness was evident in all patients after three treatments compared with pre-treatment values. Patient AMD 1 still showed cystoid intraretinal fluid formation after three treatments.

Comparison between AMD patients and healthy control group before and after three treatments
-------------------------------------------------------------------------------------------

Before treatment (baseline) there was no statistically significant difference between central and peripheral N1P1 amplitudes of the healthy group and AMD patients (AMD 1: F~1,18~ = 2.0, p = 0.2, AMD 2: F~1,18~ = 3.4, p = 0.1, AMD 3, F~1,18~ = 0.002, p = 0.9). After the third treatment central and peripheral N1P1 amplitudes significantly decreased in AMD 1 (F~1,18~ =4.3, p ≤ 0.05), AMD 2 (F~1,18~ = 3.9, p ≤ 0.05) and AMD 3 (F~1,18~ F = 6.0, p = 0.03) when compared with the healthy control group ([Figure 3](#f3-opth-1-167){ref-type="fig"}, upper panel). Central and peripheral P1 implicit times were significantly delayed before treatment in AMD 1 (F~1,18~ = 33.1, p \< 0.001) and AMD 3 (F~1,18~ = 43.4, p \< 0.001) and were not significantly different in AMD 2 (F~1,18~ = 1.8, p = 0.2) compared with the healthy group, and this did not change after three treatments ([Figure 3](#f3-opth-1-167){ref-type="fig"}, lower panel).

Comparison within pre-treatment and post-treatment values in AMD patients
-------------------------------------------------------------------------

[Table 2](#t2-opth-1-167){ref-type="table"} demonstrates the central and peripheral N1P1 response densities and P1 implicit times before and after treatments 2 and 3 for each AMD patient. There was no statistically significant change in central and peripheral N1P1 amplitudes for AMD 1 (F~1,2~ = 17, p = 0.2), AMD 2 (F~1,2~ = 55.6, p = 0.1) and and AMD 3 (F~1,2~ = 112, p = 0.1) before and after treatments 2 and 3 when compared with pre-treatment. Also, central and peripheral P1 implicit times were not significantly different to pre-treatment values in all patients (AMD 1: F~1,2~ = 8.2, p = 0.2, AMD 2: F~1,2~ = 2.5, p = 0.4 and AMD 3: F~1,2~ = 11.7, p = 0.2) after treatments 2 and 3.

[Figures 4](#f4-opth-1-167){ref-type="fig"} shows the mfERG averaged central and peripheral ring responses (a) and OCT (b) before and after three treatments with ranibizumab from AMD patient 1, AMD patient 2, and AMD patient 3. The three dimensional amplitude response density plots (c) for each patient demonstrate lower responses (as indicated in darker gray scale areas) after three treatments compared with the healthy control group.

Discussion
==========

After three treatments with ranibizumab, all AMD patients had stable or improved visual acuity and contrast sensitivity and a decrease in central macular thickness compared with pretreatment values ([Table 1](#t1-opth-1-167){ref-type="table"}). While neuroretinal function remained stable within the treatments ([Table 2](#t2-opth-1-167){ref-type="table"}), there was a significant decrease in central and peripheral mfERG amplitudes for all patients compared with a healthy age-similar group after three treatments ([Figure 3](#f3-opth-1-167){ref-type="fig"}). Our findings of no significant change compared with baseline values are in concordance with other studies investigating neuroretinal function after one treatment with anti-VEGF ([@b26-opth-1-167]; [@b30-opth-1-167]). However, these studies did not include a control group. We extend this observation to show that AMD patients have a significant reduction in amplitudes compared with an age-similar control group after three treatments.

The mfERG can measure function in localized retinal areas and in our study, areas of approximately 13.5° (central) and 13.5°--25° (peripheral) in diameter. In contrast visual acuity only reflects the function of the foveal area which is less than one degree of visual angle. The mfERG therefore better represents areas covered by the neovascularisation membrane than visual acuity. In addition although anti-VEGF targets new vessel growth, it is not clear if there are adverse effects on the healthy peripheral retina. Our findings of impaired central and peripheral neuroretinal function compared with a healthy control group after three treatments, suggest a more widespread effect of the anti-VEFG therapy on the retina than the clinically defined area affected by AMD.

In concordance with other studies we found stable or improved visual acuity. Anti-VEGF drugs reduce vascular permeability ([@b47-opth-1-167]) and a reduction in macular edema alone, could have resulted in recovery or stabilization of foveal visual acuity ([@b5-opth-1-167]). However, a reduced edema might not recover neuroretinal function. Recently [@b30-opth-1-167] reported a discrepancy between functional (visual acuity and electrophysiology) and anatomical outcomes (OCT) of patients after one bevacizumab treatment. Functional outcomes did not improve with the decrease in macular thickness after three months. They suggested that "macular edema is only a parameter that may affect visual acuity and electrophysiological responses in the beginning of the disease" ([@b30-opth-1-167]). This implies disruption of delicate intraretinal mechanisms subserving psychophysical and electrophysiological responses that do not resolve after resolution of the edema.

We are aware that patients were still undergoing treatment that was not yet complete and the recovery of neuroretinal function might occur over a longer time course. In particular amplitude recovery might take more than three treatments given that a decrease in amplitude reflects widespread cellular alteration ([@b13-opth-1-167]). However, adverse effects of anti-VEGF interfering with central and peripheral neuroretinal activity may have been evident in our mfERG results. While a lack of improvement of central neuroretinal function could have indicated the natural course of progression in AMD ([@b21-opth-1-167]), a central and peripheral functional deficit, as detected in this study, may suggest a broader, possibly adverse effect. It is well established that VEGF is essential for choriocapillaris development ([@b25-opth-1-167]). In addition VEGF has a neuroprotective role ([@b33-opth-1-167]; [@b44-opth-1-167]) and essential role in physiological angiogenesis such as the regulation of embryonic and postnatal processes ([@b12-opth-1-167]), the regulation of vascular and nervous networks in the heart and brain ([@b10-opth-1-167]; [@b27-opth-1-167]), wound healing ([@b42-opth-1-167]) and the regulation of antithrombotic processes ([@b23-opth-1-167]). Inhibition or manipulation of VEGF could be harmful in the developing retina, but also in hypoxic retinal tissue ([@b33-opth-1-167]). Hypoxia and ischemia have been discussed in AMD ([@b31-opth-1-167]; [@b16-opth-1-167], [@b17-opth-1-167]; [@b1-opth-1-167]; Feigl et al 2006) and while a normal retina might tolerate successive treatment with anti-VEGF, a hypoxic "pre-injured" retina might not.

This is the first report of the effect of multiple treatments with ranibizumab on neuroretinal function. Although we have described this effect in only a small number of patients, we want to raise awareness of possible adverse effects on the central and peripheral neuroretina. Our results should encourage large controlled trials to include vision measures other than visual acuity and OCT in documenting treatment effects of anti-VEGF therapy. Ideally these should give measures of central and peripheral neuroretinal function, as well as measures reflecting choroidal perfusion.

This work was supported by an Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology postdoctoral fellowship grant. We have benefited from discussions with Andrew J Zele.

![The mfERG uses black and white hexagons presented on a monitor (left) that flicker according to a pseudorandom m-sequence. Each waveform represents the electrical response from a hexagon which stimulates a focal retinal area. The waveforms can be plotted as a trace array (middle) or as a three dimensional response density (amplitudes per unit retinal area) plot (right). The latter reflects the distribution of the cone-mediated (photoreceptor and bipolar) cellular responses.](opth-1-167f1){#f1-opth-1-167}

![The stimulus array (right) and how the waveform responses were averaged into a central (1) and peripheral (2) area are shown. We analyzed N1P1 trough to peak amplitude response densities and P1 peak implicit times (arrows).](opth-1-167f2){#f2-opth-1-167}

![The N1P1 amplitudes ± SD (**A**) and peak implicit times ± SD (**B**) for the central and peripheral rings for each ARM patient are shown compared with a healthy control group. While P1 implicit times remained stable, N1P1 amplitudes were significantly reduced after the third treatment.](opth-1-167f3){#f3-opth-1-167}

![The mfERG and OCT results for the AMD 1 (**A**), AMD 2 (**B**) and AMD 3 (**C**) are demonstrated. The mfERG central and peripheral area waveform averages (a) and OCT images (b) before and after three treatments are shown for each patient. In c. the three dimensional response density plots of each patient compared with the age-similar control group (n = 20) are outlined before and after three treatments with ranibizumab. Note that darker gray scales indicate poorer response densities which were evident in all patients after the third treatment. These were not only reduced in the central area but throughout the whole field up to 25° (see also waveform averages in a).](opth-1-167f4){#f4-opth-1-167}

###### 

The patient's visual acuity (VA), contrast sensitivity (Contrast) and OCT

                          **VA**   **Contrast (letters)**   **OCT (microns-central 1 mm)**
  ----------------------- -------- ------------------------ --------------------------------
  **AMD 1 (left eye)**                                      
  Before                  6/30     21                       319
  After 2                 6/30     21                       200
  After 3                 6/48     24                       223
  **AMD 2 (left eye)**                                      
  Before                  6/9.5    34                       388
  After 2                 6/9.5    34                       194
  After 3                 6/9.5    34                       201
  **AMD 3 (right eye)**                                     
  Before                  6/30     23                       279
  After 2                 6/15     26                       237
  After 3                 6/7.5    33                       245

###### 

The central and peripheral N1P1 response density (above) and P1 implicit time

  **N1P1 in nV/deg^2^**   **Before**   **After 2**   **After 3**                          
  ----------------------- ------------ ------------- ------------- ------------ --------- ------------
  Area                    central      peripheral    central       peripheral   central   peripheral
  **AMD 1**               3.7          3.1           2.8           2.1          3.2       2.1
  **AMD 2**               3.7          2.2           5.2           2.6          3.7       1.8
  **AMD 3**               5.6          4.3           3.1           2.0          2.9       1.6

  **P1 in ms**   **Before**   **After 2**   **After 3**                          
  -------------- ------------ ------------- ------------- ------------ --------- ------------
  Area           central      peripheral    central       peripheral   central   peripheral
  **AMD 1**      36.6         35.4          37.5          37.5         35.0      35.4
  **AMD 2**      31.3         29.2          31.3          29.6         31.7      30.4
  **AMD 3**      37.1         37.1          31.7          31.7         35.5      36.7

**Note:** (below) values before and after treatment 2 and 3 for each AMD patient.
